State medical boards adopt telemedicine safety guidelines

Representatives of state medical licensing boards have approved updated guidelines to help ensure the safety and quality of medicine when it is practiced using telemedicine technology.

The Model Policy on the Appropriate Use of Telemedicine Technologies in the Practice of Medicine, adopted by the Federation of State Medical Boards (FSMB), provides guidance and a basic roadmap that state boards can use to ensure that patients are protected from harm.

Among its key provisions, the model policy states that the same standards of care that have historically protected patients during in-person medical encounters must apply to medical care delivered electronically. Care providers using telemedicine must establish a credible “patient-physician relationship,” ensuring that patients are properly evaluated and treated and that providers adhere to well-established principles guiding privacy and security of personal health information, informed consent, safe prescribing and other key areas of medical practice.

“Telemedicine offers wonderful tools to help expand treatment options for patients–particularly in helping provide care in remote areas, lowering costs and helping support preventive care efforts,” said FSMB President and CEO Humayun J. Chaudhry, DO, MACP, in a release. “But as telemedicine has grown, so too has the need for clear, common-sense guidelines that help healthcare providers transition to this exciting new environment in a safe way.”

The new guidelines are designed to provide flexibility in the use of technology by physicians–ranging from telephone and email interactions to videoconferencing–as long as they adhere to widely recognized standards of patient care.

The policy adopted by the FSMB’s House of Delegates, which represents all of the nation’s 70 state and territorial state medical licensing boards, is advisory, meaning state boards are free to adopt it as is, modify it or retain their own current policies regarding telemedicine.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.